PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 34, issue 12, 2016

Using Best–Worst Scaling to Investigate Preferences in Health Care pp. 1195-1209

Kei Long Cheung, Ben F. M. Wijnen, Ilene L. Hollin, Ellen M. Janssen, John F. Bridges, Silvia M. A. A. Evers and Mickael Hiligsmann

Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review pp. 1211-1225

Surasak Saokaew, Ajaree Rayanakorn, David Bin-Chia Wu and Nathorn Chaiyakunapruk

The Value of Medicines: A Crucial but Vague Concept pp. 1227-1239

Fernando Antoñanzas, Robert Terkola and Maarten Postma

Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1241-1253

Rachid Rafia, Alison Scope, Sue Harnan, John W. Stevens, Matt Stevenson and Alan Lobo

Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study pp. 1255-1265

Pei-Jung Lin, Cayla J. Saret, Peter J. Neumann, Eileen A. Sandberg and Joshua T. Cohen

The Pharmacoeconomic Evaluation Process in Ireland pp. 1267-1276

Laura McCullagh and Michael Barry

Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases pp. 1277-1297

Paul S. J. Miller, Harry Hill and Fredrik L. Andersson

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model pp. 1299-1308

Christiaan Dolk, Martin Eichner, Robert Welte, Anastassia Anastassopoulou, Laure-Anne Van Bellinghen, Barbara Poulsen Nautrup, Ilse Van Vlaenderen, Ruprecht Schmidt-Ott, Markus Schwehm and Maarten Postma

Volume 34, issue 11, 2016

From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare pp. 1071-1074

Matthijs Versteegh, Saskia Knies and Werner Brouwer

Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation pp. 1075-1086

Padraig Dixon, George Davey Smith, Stephanie von Hinke, Neil M. Davies and William Hollingworth

Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies pp. 1087-1100

Feng Xie, Bruno Kovic, Xuejing Jin, Xiaoning He, Mengxiao Wang and Camila Silvestre

The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence pp. 1101-1110

Eleftherios Sideris, Mark Corbett, Stephen Palmer, Nerys Woolacott and Laura Bojke

A Methodological Review of US Budget-Impact Models for New Drugs pp. 1111-1131

Josephine Mauskopf and Stephanie Earnshaw

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis pp. 1133-1144

Matthijs Versteegh

Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK pp. 1145-1159

Jamie Elvidge, Ash Bullement and Anthony J. Hatswell

Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations pp. 1161-1172

Cynthia P. Iglesias, Alexander Thompson, Wolf H. Rogowski and Katherine Payne

Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience pp. 1173-1186

François Bocquet, Anaïs Loubière, Isabelle Fusier, Anne-Laure Cordonnier and Pascal Paubel

Discretely Integrated Condition Event Simulation for Pharmacoeconomics pp. 1187-1188

Mondher Toumi, Ekkehard Beck, Steve Sherman, Leyla Mohseninejad and Samuel Aballéa

Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics pp. 1189-1190

J. Jaime Caro

Volume 34, issue 10, 2016

Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions? pp. 967-969

Livio Garattini and Alessandro Curto

Sustainable Financing of Innovative Therapies: A Review of Approaches pp. 971-980

Aidan Hollis

Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence pp. 981-992

Alexis Llewellyn, Rita Faria, Beth Woods, Mark Simmonds, James Lomas, Nerys Woolacott and Susan Griffin

EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes pp. 993-1004

Mark Oppe, Kim Rand-Hendriksen, Koonal Shah, Juan M. Ramos‐Goñi and Nan Luo

The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan pp. 1005-1014

Haruhisa Fukuda, Shunya Ikeda, Takeru Shiroiwa and Takashi Fukuda

Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3 pp. 1015-1022

Ron D. Hays, Dennis A. Revicki, David Feeny, Peter Fayers, Karen L. Spritzer and David Cella

A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy pp. 1023-1038

Paul Tappenden, Shijie Ren, Rachel Archer, Rebecca Harvey, Marrissa Martyn-St James, Hasan Basarir, John Stevens, Alan Lobo and Sami Hoque

Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer pp. 1039-1050

Bonny Parkinson, Rosalie Viney, Marion Haas, Stephen Goodall, Preeyaporn Srasuebkul and Sallie-Anne Pearson

BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles pp. 1051-1065

William C. N. Dunlop, C. Daniel Mullins, Olaf Pirk, Ron Goeree, Maarten J. Postma, Ashley Enstone and Louise Heron

Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter? pp. 1067-1070

T. Joseph Mattingly, C. Daniel Mullins and Eberechukwu Onukwugha

Volume 34, issue 9, 2016

Model Validation: Has it’s Time Come? pp. 829-831

Jonathan Karnon

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer pp. 833-845

Pieter T. Boer, Geert W. J. Frederix, Talitha L. Feenstra and Pepijn Vemer

Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches pp. 847-861

Joshua Pink, Ben Parker and Stavros Petrou

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence pp. 901-912

James Lomas, Alexis Llewellyn, Marta Soares, Mark Simmonds, Kath Wright, Alison Eastwood and Stephen Palmer

Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial pp. 913-923

Stéphane Verguet, Jane J. Kim and Dean T. Jamison

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland pp. 925-937

Susanne Schmitz, Laura McCullagh, Roisin Adams, Michael Barry and Cathal Walsh

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland pp. 939-951

Lisa Nagy, Terho Heikkinen, Alfred Sackeyfio and Richard Pitman

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting pp. 953-966

Melanie J. Davies, Divina Glah, Barrie Chubb, Gerasimos Konidaris and Phil McEwan

Volume 34, issue 8, 2016

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges pp. 723-731

Sevan Dirmesropian, James G. Wood, C. Raina MacIntyre, Philippe Beutels and Anthony T. Newall

Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective pp. 741-750

P. Thokala, E. L. Simpson, P. Tappenden, J. W. Stevens, K. Dickinson, S. Ryder and P. Harrison

The Impact of Different DCE-Based Approaches When Anchoring Utility Scores pp. 805-814

Richard Norman, Brendan Mulhern and Rosalie Viney

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria pp. 815-827

Jonathan Graham, Doreen McBride, Donald Stull, Anna Halliday, Stamatia Theodora Alexopoulos, Maria-Magdalena Balp, Matthew Griffiths, Ion Agirrezabal, Torsten Zuberbier and Alan Brennan

Volume 34, issue 7, 2016

Why Cancer? pp. 625-627

Alan Haycox

Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine pp. 635-644

Gregory S. Zaric

Health, Health-Related Quality of Life, and Quality of Life: What is the Difference? pp. 645-649

Milad Karimi and John Brazier

Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches pp. 651-664

James Shearer, Paul McCrone and Renee Romeo

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 673-680

Hazel Squires, Matt Stevenson, Emma Simpson, Rebecca Harvey and John Stevens

Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease pp. 681-707

Luis Hernandez, Asli Ozen, Rodrigo DosSantos and Denis Getsios

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia pp. 709-721

Krithika Rajagopalan, David Trueman, Lydia Crowe, Daniel Squirrell and Antony Loebel

Volume 34, issue 6, 2016

Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective pp. 529-531

Kenneth Boyd and Peter Hall

Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension pp. 533-550

Shuyan Gu, Huimei Hu and Hengjin Dong

Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals pp. 551-567

Jagpreet Chhatwal, Tianhua He and Maria A. Lopez-Olivo

A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus pp. 569-585

Martin Henriksson, Ramandeep Jindal, Catarina Sternhufvud, Klas Bergenheim, Elisabeth Sörstadius and Michael Willis

Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence pp. 587-596

Sebastian Hinde, Ros Wade, Stephen Palmer, Nerys Woolacott and Eldon Spackman

Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement pp. 597-608

Suzy Paisley

Biosimilars: How Can Payers Get Long-Term Savings? pp. 609-616

Jorge Mestre-Ferrandiz, Adrian Towse and Mikel Berdud

Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health pp. 617-624

Salah Ghabri, Françoise F. Hamers and Jean Michel Josselin

Volume 34, issue 5, 2016

Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One? pp. 423-426

Livio Garattini, Alessandro Curto and Nick Freemantle

Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right? pp. 427-433

Beth Woods, Rita Faria and Susan Griffin

Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment pp. 435-446

Aris Angelis and Panos Kanavos

Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches pp. 447-461

Dyfrig Hughes, Joanna Charles, Dalia Dawoud, Rhiannon Tudor Edwards, Emily Holmes, Carys Jones, Paul Parham, Catrin Plumpton, Colin Ridyard, Huw Lloyd-Williams, Eifiona Wood and Seow Tien Yeo

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 463-477

Abdullah Pandor, Daniel Pollard, Tim Chico, Robert Henderson and Matt Stevenson

Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature pp. 479-498

Simon Frey, Carl Blankart and Tom Stargardt

Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care pp. 499-508

Joanna Coast, Elisabeth Huynh, Philip Kinghorn and Terry Flynn

Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study pp. 509-520

Kathryn Coyle, Doug Coyle, Julie Blouin, Karen Lee, Mohammed F. Jabr, Khai Tran, Lisa Mielniczuk, John Swiston and Mike Innes

EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria pp. 521-527

Emma Hawe, Doreen McBride, Maria-Magdalena Balp, Haijun Tian, Anna Halliday and Donald E. Stull

Volume 34, issue 4, 2016

Should the Lambda (λ) Remain Silent? pp. 323-329

Hossein Haji Ali Afzali, Jonathan Karnon and Mark Sculpher

Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright: Cost Effectiveness Modelling for Health Technology Assessment: A Practical Course pp. 331-332

Doug Coyle

Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility pp. 333-336

Alexander Thompson, Bruce Guthrie and Katherine Payne

The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence pp. 337-348

Joanne O’Connor, Stephen Rice, Alison Smith, Mark Rodgers, Rocio Rodriguez Lopez, Dawn Craig and Nerys Woolacott

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users pp. 349-361

P. Vemer, I. Corro Ramos, G. A. K. Voorn, M. J. Al and T. L. Feenstra

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France pp. 363-391

Sylvain Druais, Agathe Doutriaux, Magali Cognet, Annabelle Godet, Christophe Lançon, Pierre Levy, Ludovic Samalin and Pascal Guillon

What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study pp. 393-402

Anthony Harris, Jing Jing Li and Karen Yong

Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa pp. 403-417

Ilanca Fraser, Johanita Burger, Martie Lubbe, George Dranitsaris, Mark Sonderup and Tienie Stander

Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review” pp. 419-420

Angelo Claudio Palozzo and Andrea Messori

Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’ pp. 421-422

Bonny Parkinson and Adam G. Elshaug

Volume 34, issue 3, 2016

PCSK9 Inhibitors: A Technology Worth Paying For? pp. 217-220

William S. Weintraub and Samuel S. Gidding

PCSK9 Inhibitors: A Technology Worth Paying For? pp. 217-220

William Weintraub and Samuel Gidding

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering? pp. 221-224

Livio Garattini, Anna Padula and Milene Rangel Costa

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering? pp. 221-224

Livio Garattini, Anna Padula and Milene Costa

Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century pp. 225-226

Suzanne Rose Hill

Zaheer-Ud-Din Babar (ed): Pharmaceutical Prices in the 21st Century pp. 225-226

Suzanne Hill

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community pp. 227-244

Bernhard Ultsch, Oliver Damm, Philippe Beutels, Joke Bilcke, Bernd Brüggenjürgen, Andreas Gerber-Grote, Wolfgang Greiner, Germaine Hanquet, Raymond Hutubessy, Mark Jit, Mirjam Knol, Rüdiger Kries, Alexander Kuhlmann, Daniel Levy-Bruhl, Matthias Perleth, Maarten Postma, Heini Salo, Uwe Siebert, Juergen Wasem and Ole Wichmann

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community pp. 227-244

Bernhard Ultsch, Oliver Damm, Philippe Beutels, Joke Bilcke, Bernd Brüggenjürgen, Andreas Gerber-Grote, Wolfgang Greiner, Germaine Hanquet, Raymond Hutubessy, Mark Jit, Mirjam Knol, Rüdiger Kries, Alexander Kuhlmann, Daniel Levy-Bruhl, Matthias Perleth, Maarten Postma, Heini Salo, Uwe Siebert, Juergen Wasem and Ole Wichmann

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 245-257

Munira Essat, Paul Tappenden, Shijie Ren, Alice Bessey, Rachel Archer, Ruth Wong, Alan Lobo and Sami Hoque

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 245-257

Munira Essat, Paul Tappenden, Shijie Ren, Alice Bessey, Rachel Archer, Ruth Wong, Alan Lobo and Sami Hoque

Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges pp. 259-272

Jordana K. Schmier and Carolyn K. Hulme-Lowe

Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges pp. 259-272

Jordana Schmier and Carolyn Hulme-Lowe

Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care pp. 273-284

Terry N. Flynn, Marcel Bilger, Chetna Malhotra and Eric A. Finkelstein

Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care pp. 273-284

Terry Flynn, Marcel Bilger, Chetna Malhotra and Eric Finkelstein

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation pp. 285-301

Monika Wagner, Hanane Khoury, Jacob Willet, Donna Rindress and Mireille Goetghebeur

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation pp. 285-301

Monika Wagner, Hanane Khoury, Jacob Willet, Donna Rindress and Mireille Goetghebeur

Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania pp. 303-314

Amani Thomas Mori, Ole Frithjof Norheim and Bjarne Robberstad

Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania pp. 303-314

Amani Mori, Ole Norheim and Bjarne Robberstad

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives pp. 315-322

Jill Bindels, Bram Ramaekers, Isaac Corro Ramos, Leyla Mohseninejad, Saskia Knies, Janneke Grutters, Maarten Postma, Maiwenn Al, Talitha Feenstra and Manuela Joore

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives pp. 315-322

Jill Bindels, Bram Ramaekers, Isaac Ramos, Leyla Mohseninejad, Saskia Knies, Janneke Grutters, Maarten Postma, Maiwenn Al, Talitha Feenstra and Manuela Joore

Volume 34, issue 2, 2016

Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis pp. 91-93

Eberechukwu Onukwugha

Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis pp. 91-93

Eberechukwu Onukwugha

Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models pp. 95-100

William H. Crown

Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models pp. 95-100

William Crown

Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats pp. 101-106

Brendan Collins

NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data pp. 107-114

Owen A. Johnson, Peter S. Hall and Claire Hulme

NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data pp. 107-114

Owen Johnson, Peter Hall and Claire Hulme

Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research pp. 115-126

Deborah A. Marshall, Lina Burgos-Liz, Kalyan S. Pasupathy, William V. Padula, Maarten J. IJzerman, Peter K. Wong, Mitchell K. Higashi, Jordan Engbers, Samuel Wiebe, William Crown and Nathaniel D. Osgood

Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research pp. 115-126

Deborah Marshall, Lina Burgos-Liz, Kalyan Pasupathy, William Padula, Maarten IJzerman, Peter Wong, Mitchell Higashi, Jordan Engbers, Samuel Wiebe, William Crown and Nathaniel Osgood

National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment pp. 127-138

Nalin Payakachat, J. Mick Tilford and Wendy J. Ungar

National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment pp. 127-138

Nalin Payakachat, J. Tilford and Wendy Ungar

Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015 pp. 139-154

Paula Lorgelly, Brett Doble and Rachel J. Knott

Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015 pp. 139-154

Paula Lorgelly, Brett Doble and Rachel Knott

Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities pp. 155-160

Miqdad Asaria, Katja Grasic and Simon Walker

Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities pp. 155-160

Miqdad Asaria, Katja Grasic and Simon Walker

Validation of the Hospital Episode Statistics Outpatient Dataset in England pp. 161-168

Joanna C. Thorn, Emma Turner, Luke Hounsome, Eleanor Walsh, Jenny L. Donovan, Julia Verne, David E. Neal, Freddie C. Hamdy, Richard M. Martin and Sian M. Noble

Validation of the Hospital Episode Statistics Outpatient Dataset in England pp. 161-168

Joanna Thorn, Emma Turner, Luke Hounsome, Eleanor Walsh, Jenny Donovan, Julia Verne, David Neal, Freddie Hamdy, Richard Martin and Sian Noble

Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data pp. 169-179

Margrét V. Bjarnadóttir, Sana Malik, Eberechukwu Onukwugha, Tanisha Gooden and Catherine Plaisant

Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data pp. 169-179

Margrét Bjarnadóttir, Sana Malik, Eberechukwu Onukwugha, Tanisha Gooden and Catherine Plaisant

Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment pp. 181-194

Caroline Canavan, Joe West and Timothy Card

Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment pp. 181-194

Caroline Canavan, Joe West and Timothy Card

Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease pp. 195-205

Chris Schilling, Duncan Mortimer, Kim Dalziel, Emma Heeley, John Chalmers and Philip Clarke

Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease pp. 195-205

Chris Schilling, Duncan Mortimer, Kim Dalziel, Emma Heeley, John Chalmers and Philip Clarke

Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases pp. 207-216

Eberechukwu Onukwugha, Ran Qi, Jinani Jayasekera and Shujia Zhou

Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases pp. 207-216

Eberechukwu Onukwugha, Ran Qi, Jinani Jayasekera and Shujia Zhou

Volume 34, issue 1, 2016

Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016 pp. 1-3

Yot Teerawattananon and Alia Luz

Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016 pp. 1-3

Yot Teerawattananon and Alia Luz

The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System? pp. 5-11

James F. O’Mahony and Diarmuid Coughlan

The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System? pp. 5-11

James O’Mahony and Diarmuid Coughlan

Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers pp. 13-22

Elamin H. Elbasha and Jagpreet Chhatwal

Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers pp. 13-22

Elamin Elbasha and Jagpreet Chhatwal

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene pp. 23-31

Hedwig Blommestein, Nigel Armstrong, Steve Ryder, Sohan Deshpande, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen, Johan Severens and Maiwenn Al

The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial pp. 33-42

David Meads, Andrea Marshall, Claire Hulme, Janet Dunn and Hugo Ford

Cost-of-Illness Studies: An Updated Review of Current Methods pp. 43-58

Eberechukwu Onukwugha, Jacquelyn McRae, Alex Kravetz, Stefan Varga, Rahul Khairnar and C. Mullins

Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries pp. 59-76

Emelie Heintz, Andreas Gerber-Grote, Salah Ghabri, Francoise F. Hamers, Valentina Prevolnik Rupel, Renata Slabe-Erker and Thomas Davidson

Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries pp. 59-76

Emelie Heintz, Andreas Gerber-Grote, Salah Ghabri, Francoise Hamers, Valentina Rupel, Renata Slabe-Erker and Thomas Davidson

Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada pp. 77-90

William Herring, Isobel Pearson, Molly Purser, Hamid Reza Nakhaipour, Amin Haiderali, Sorrel Wolowacz and Kavisha Jayasundara

Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada pp. 77-90

William Herring, Isobel Pearson, Molly Purser, Hamid Nakhaipour, Amin Haiderali, Sorrel Wolowacz and Kavisha Jayasundara